VCRE (Vicore Pharma Holding AB) Debt-to-EBITDA : 0.00 (As of Mar. 2026)

What is Vicore Pharma Holding AB Debt-to-EBITDA?

Vicore Pharma Holding AB VCRE -4.00% 13 Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus rates VCRE with a GF Score™ of 13/100. The stock has 5 warning signs investors should review. Among 290 Biotechnology companies, Vicore Pharma Holding AB ranks worse than 344827.24% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vicore Pharma Holding AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Vicore Pharma Holding AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Vicore Pharma Holding AB's annualized EBITDA for the quarter that ended in Mar. 2026 was $-46.32 Mil. Vicore Pharma Holding AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Vicore Pharma Holding AB's Debt-to-EBITDA or its related term are showing as below:

VCRE's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.15
* Ranked among companies with meaningful Debt-to-EBITDA only.

Vicore Pharma Holding AB (NAS:VCRE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Vicore Pharma Holding AB Debt-to-EBITDA Related Terms

Vicore Pharma Holding AB Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Debt-to-EBITDA Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Debt-to-EBITDA

Get a 7-Day Free Trial

0.00

Vicore Pharma Holding AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Debt-to-EBITDA	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

VCRE vs : Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vicore Pharma Holding AB Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Debt-to-EBITDA falls into.

Save Embed

13GF Score

Vicore Pharma Holding AB VCRE

Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vicore Pharma Holding AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Vicore Pharma Holding AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-51.371
	=	0.00

Vicore Pharma Holding AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2026 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-46.316
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →

What does a Debt-to-EBITDA of 0.00 mean?

Vicore Pharma Holding AB (VCRE) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vicore Pharma Holding AB. According to the industry distribution chart, Vicore Pharma Holding AB ranks #999999 out of 290 companies in the Biotechnology industry.

Is Vicore Pharma Holding AB's Debt-to-EBITDA too high?

Vicore Pharma Holding AB's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Vicore Pharma Holding AB ranks #999999 out of 290 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vicore Pharma Holding AB has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.

How does Vicore Pharma Holding AB's Debt-to-EBITDA compare to ?

According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #999999 out of 290 companies for Debt-to-EBITDA. This places Vicore Pharma Holding AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-EBITDA for a Biotechnology company?

The median Debt-to-EBITDA among Biotechnology companies is 1.15, based on 290 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-EBITDA mean?

A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Vicore Pharma Holding AB. For the Biotechnology industry, the median Debt-to-EBITDA is 1.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vicore Pharma Holding AB's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vicore Pharma Holding AB stock overvalued right now?

Vicore Pharma Holding AB (VCRE) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Vicore Pharma Holding AB's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-EBITDA calculated?

Debt-to-EBITDA is calculated from a company's financial statements. For Vicore Pharma Holding AB (VCRE), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Industry Healthcare Biotechnology

Comparable Companies

Other Exchanges VICO:Sweden 6Y4:Germany

Address Kornhamnstorg 53, Stockholm, SWE, 111 27

Website https://www.vicorepharma.com

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

13GF Score

Get the complete analysis for VCRE

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.60

Price

View VCRE Analysis

See Debt-to-EBITDA data for all stocks →